# Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

> **NCT02314208** · PHASE2 · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 12 (actual)

## Conditions studied

- Spastic Paraplegia, Hereditary

## Interventions

- **DRUG:** Xenbilox
- **DIETARY_SUPPLEMENT:** Resveratrol
- **DRUG:** Tahor

## Key facts

- **NCT ID:** NCT02314208
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-08
- **Primary completion:** 2017-09-27
- **Final completion:** 2018-01-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02314208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02314208, "Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02314208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*